Predictors of smoke-free workplaces by employee characteristics: who is left unprotected?

Background: Over the last decade, there has been steady progress in the adoption of workplace smoking policies in the United States. However, the benefits of a smoke-free workplace are not distributed equally among the workforce.

Methods: Data from 44,357 adults who reported that they work indoors were derived from an optional tobacco module on the 2001 Behavioral Risk Factor Surveillance System (BRFSS), administered by 25 states.

Bidi cigarette use among young adults in 15 states.

Background: There is a paucity of research on bidi use in the US and the few studies conducted have focused solely on adolescents. This article describes patterns and explores factors associated with bidi use among young adults, aged 18-24.

Methods: Data from 63,728 adults, including 5,324 young adults, aged 18-24, were derived from an optional tobacco module on the 2001 Behavioral Risk Factor Surveillance System, administered by 15 states.

Advances in pharmacotherapy for tobacco dependence.

The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance.